The plasticity of a cell is one of its quietly profound advantages picture cells glowing from an extraneous DNA vector incorporated into the genome or cells that acquire newfound targeting abilities to find and kill problematic tumors.
Superpowered cells cloaked with superhuman abilities are what unify the burst of engineered cell therapies that are exploding on the biopharmaceutical scene. This includes chimeric antigen receptor(CAR)-T cell therapies, where different cell types are armored with receptors that can latch onto and kill cancer cells. Or,reprogrammed stem cellsthat replace certain cell types lost during diseases like diabetes, as well asCRISPR-Cas9 editingof existing cells to correct blindness.
These exciting therapeutic possibilities have created a whole host of new questions: how, for instance, can we mass manufacture enough personalized cells to satisfy millions of patients? How can we ensure therapeutic quality? How can we truly understand that the changes made to these cells are helpful to the patient rather than harmful?
Several biotechnology companies are pushing to answer some of those questions.Cellaresis focused on creating a solution to the issue of mass manufacturing.Mission Bioisdeveloping sequencing platforms that can better understand the genetic changes in cell therapies and various patients. Both companies are part of the rapidly evolving push to create and characterize the superhuman powers cells can be endowed with.
Cellares aims to develop scalability hoping for a cell therapy future without engineering bottlenecks. Earlier this year, the company raised$82 million in Series B fundingto continue the development of their Cell Shuttle, a cell therapy factory-in-a-box that aims to fully automate cell therapy workflows.
2017 marked the beginning of the commercialization phase in cell therapies when the first CAR-T cell therapies were FDA-approved. Prior to that, nobody was faced with the challenge of how you could scale this out to tens and hundreds of thousands of patients per year, per drug, said Fabian Gerlinghaus, CEO at Cellares. The problem is new, and the problem is unsolved.
Cellares technology revolves around their GMP (good manufacturing practice)-in-a-box cartridge. The cartridge is a single use consumable that reduces the need for human action to merely load and unload the cells. On a larger scale, the Cell Shuttle system is the combination of cartridges and various bioprocessing instruments contained inside a robotic work cell that maintains an enclosed GMP environment. The process becomes user-controlled and customized through a centralized software solution.
According to Gerlinghaus, the very capability to load 10 cartridges at once allows for a dramatic escalation in manufacturing capacity. Additionally, the components that make up the Cell Shuttle allow for a high degree of customer and, subsequently patient, personalization. You can run 10 different processes with different process parameters and workflows simultaneously on the same platform, he explained. High level customization happens by choosing which of our modular instruments were actually going to be putting on the Cell Shuttle to support your workflow. Low-level customization to a particular process happens in user-facing software, which leverages the flexibility of our modular system architecture.
Capability-wise, Gerlinghaus stated that the Cell Shuttle supports all of the typical cellular manufacturing unit operations, which include cell enrichment, selection systems, cell activation, non-viral/viral gene transfer, cell washing, media or buffer changes, and automated sampling.
The entire design intent with our software platform is to put the power into the hands of process development scientists or pharma companies to create and run the processes that define their products, he added.
While Cellares tackles the problem of mass-manufacturing cell therapies, the question of understanding genomic changes both in the cell therapy and in the patient themselves persists. This is where Mission Bio carves a niche for itself. The biotechnology company uses single-cell DNA sequencing and multi-nomics approaches to understand, on a per-cell basis, how certain perturbations change the genome.
Mission Bios Tapestri platform utilizes a microfluidics-based approach to simultaneously sequence targeted DNA and identify cell-surface proteins in individual cells. First, a single-cell suspension is generated by the scientist. This suspension is incubated with oligo-conjugated antibodies, which recognize and tag specific proteins. The solution is loaded onto the Tapestri platform, where each cell is encapsulated into a droplet. Within each droplet, a protease reaction first digests the chromatin surrounding DNA.
Next, each droplet flows into a second, separate droplet, where targeted DNA and protein tags are amplified through a polymerase chain reaction, allowing for subsequent amplification and sequencing. Ultimately, the read-out includes the genotype and immunophenotype to portray a more holistic picture of the cells genome.
Why, then, choose to leverage sequencing technology on a single cell level as opposed to a bulk level? When we do bulk [sequencing], we assume that the sample is homogeneous, said Dr. Yan Zhang, PhD, CEO at Mission Bio. But that is not true. We know that biological samples are heterogeneous. If you just use bulk sequencing, you cannot get a high level of specificity.
While sequencing technologies (some offering single cell resolution) have become highly popularized in recent years, Mission Bios Tapestri is crucially different from the popular RNA-sequencing platforms dominating the field today. Rather than looking at gene expression, as is the goal of RNA-sequencing, Tapestri looks at the genome itself. This is particularly useful for diseases like cancer, where patients can have drastically variable DNA mutations in certain cells that would render one drug more effective than another. This is also useful for cell engineering, where traditional quality-control methods rely on growing out single cell clones for selection and downstream genome analysis a time-consuming task.
Zhang raised the example of scientists aiming to CRISPR-edit cells, where a potential goal is to make 27 separate edits in a single cell. Without single cell sequencing resolution, it is difficult to identify which cells have been reprogrammed with all 27 edits, as opposed to 3 or even 26 of those edits. With our technology, they could distinguish [the cells with all 27 edits], Zhang said. They were able to optimize the conditions improving the desired edit efficiency from 2% to 50%.
In the future, Zhang hopes that Tapestri will be leveraged as a strategy to monitor the cells of patients undergoing cell or gene therapy. The desire for cell and gene therapy is to cure patients with a single dose that can last for a lifetime, she explained. But its still very early, and we still need to understand and monitor the patients. Our technology, at least how we see it, is extremely powerful for accelerating development, giving you much better insight into safety, efficacy, toxicity, and metabolism.
Mission Bio has recently releasedTapestri Cell & Gene Therapy Solutions, aimed towards quickly characterizing genetically edited, superpowered cells in cell and gene therapy development pipelines. Meanwhile, Cellares continues to develop its Cell Shuttle, with an anticipated market release in late 2023. Both companies are actively pursuing partnerships to both broaden and develop their technologies. Tapestri has been cited in papers tracingCRISPR-edited cellsandleukemia, while Cellares announced a partnership withPoseida Therapeuticsas part of their Early Access Program.
Altogether, the journey to create and understand a superpowered cell continues. For Gerlinghaus, a former aerospace engineer, this commitment to ensuring quality and scale, combined with special powers, persists. Were taking a very systematic approach, which ultimately will result in a very reliable solution for pharma companies that ultimately benefits patients, he said. The level of reliability that were going for with our equipment is akin to the level of reliability of an airplane."
Read the rest here:
- Here's Why Longeveron Is Surging Today - Motley Fool - December 4th, 2021
- Global Regenerative Medicine Partnering Report/Directory 2021: Terms and Agreements for 1600 Deals 2014-2 - Benzinga - December 4th, 2021
- CAR T-Cell Therapy Market is anticipated to reach US$ 2.8 Bn by 2031 - PRNewswire - December 4th, 2021
- Stem-cell implant prototypes pave the way towards life-long treatment for type 1 diabetes - ZME Science - December 3rd, 2021
- Certain Patients With Heart Failure May Benefit From Stem Cell Therapy - Pharmacy Times - December 3rd, 2021
- Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update - Yahoo Finance - December 3rd, 2021
- Roundtable Discussion: Usmani and Participants Review Using Transplant and Combination Therapy in a Patient With Newly Diagnosed Multiple Myeloma -... - December 3rd, 2021
- Hematopoiesis and innate immunity: an inseparable couple for good and bad times, bound together by an hormetic relationship - DocWire News - December 3rd, 2021
- Reality of universal cancer prevention & cure - BSA bureau - December 3rd, 2021
- World Aids Day Improving the lives of everyone affected by HIV - QMUL - December 3rd, 2021
- Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of... - December 3rd, 2021
- AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and... - November 28th, 2021
- The questions surgical robots still need to answer - Becker's Orthopedic & Spine - November 24th, 2021
- Holiday Gift Guide 2021: The Best Wellness And Self-Care Essentials For Travel - Forbes - November 24th, 2021
- Investigating pathogens and their life cycles, for the benefit of society - MIT News - November 24th, 2021
- Mitigating Toxicities Will Position BCMA for Role in Triple-Class Refractory Multiple Myeloma - OncLive - November 24th, 2021
- Human Primary Cells Market 2021 | Know the Latest COVID19 Impact Analysis and Strategies of Key Players: Lonza, Thermo Fisher Scientific,... - November 21st, 2021
- Researcher Works for Diversity, Inclusion in Sciences, One Journal at a Time - Lab Manager Magazine - November 18th, 2021
- Raw Marijuana Won't Get You Stoned, But It Does Have Some Interesting Benefits - Benzinga - Benzinga - November 16th, 2021
- The 18 Best New November 2021 Skin-Care Launches That Deserve a Spot in Your Routine - Allure - November 16th, 2021
- Singapore Aims To Lead The World In Lab-Grown Meat - Intelligent Living - November 16th, 2021
- Dermarolling Your Scalp Is Proven to Increase Hair Growth and Thickness Here's How to Do It - Yahoo Lifestyle - November 15th, 2021
- Stem Cell Therapy for Heart Failure Reduces CV Events, Death in Select Patientsbut not Hospitalization - AJMC.com Managed Markets Network - November 15th, 2021
- JASPER THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com - November 15th, 2021
- Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million - Seeking Alpha - November 15th, 2021
- Beam gets green light to begin first clinical test of base editing - BioPharma Dive - November 15th, 2021
- GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting and Exposition - Galveston County... - November 15th, 2021
- Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference - GlobeNewswire - November 11th, 2021
- Fate Therapeutics Announces Abstract Highlighting FT538 and - GlobeNewswire - November 11th, 2021
- Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer... - November 11th, 2021
- Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress - KULR-TV - November 11th, 2021
- Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference - Yahoo Finance - November 9th, 2021
- CELLECTAR BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com - November 9th, 2021
- Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic - PRNewswire - November 9th, 2021
- Technology set to redesign the future of food as agriculture moves towards net zero - ABC News - November 9th, 2021
- MAGENTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - marketscreener.com - November 5th, 2021
- Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology... - November 5th, 2021
- 15 Best Peptide Skin-Care Products 2021 for Smoother, Firmer, and Plumper Skin - Allure - November 5th, 2021
- Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of... - November 5th, 2021
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results - GlobeNewswire - November 5th, 2021
- Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting - The Bakersfield Californian - November 5th, 2021
- STEMTECH CORPORATION (OTC:GNTW) ANNOUNCES APPOINTMENT OF SANDRA KAZICKAITE TO THE ROLE OF VICE PRESIDENT OF GLOBAL PERFORMANCE - Yahoo Finance - November 3rd, 2021
- Assessing the benefits of stem cell research (column) - LNP | LancasterOnline - November 1st, 2021
- How to Test for Leukemia: What Are My Options? - Healthline - November 1st, 2021
- Exposed: The Plague Of Fake Medical Trials Putting Lives In Danger - Todayuknews - Todayuknews - November 1st, 2021
- To Reduce Stress and Boost Energy, Try Maca Root - The Beet - November 1st, 2021
- In Vitro Toxicology Testing Market Outlook 2021 Pricing Strategy, Industry Latest News, Top Company Analysis, Research Report Analysis and Share by... - November 1st, 2021
- Geron Enters New Innovative Licensing and Access Pathway in the United Kingdom for Imetelstat - Business Wire - November 1st, 2021
- Stem Cell Diseases: What Can Stem Cells Cure | stemcela.com - October 30th, 2021
- The Cost Of Stem Cell Therapy in 2021 | BioInformant - October 30th, 2021
- NIH Guidelines for Human Stem Cell Research | STEM Cell ... - October 30th, 2021
- Fi Europe 2021 innovation finalists mirror mega trends of plant based and sustainability - FoodNavigator.com - October 30th, 2021
- Types of Oncology Drugs - Healthline - October 28th, 2021
- Medical Innovation In Pet Healthcare Is Taking Things Up a Notch - Entrepreneur - October 28th, 2021
- BIOHAVEN ENROLLS PHASE 1A/1B CLINICAL TRIAL OF BHV-1100, LEAD ASSET FROM ITS ARM (ANTIBODY RECRUITING MOLECULE) PLATFORM, IN COMBINATION WITH NK CELL... - October 28th, 2021
- Researchers discover a way to increase the effectiveness of antibiotics - EurekAlert - October 28th, 2021
- Fresh Bros: Exploring the Top Five Health Benefits of Turmeric Extract with BioPerine - GlobeNewswire - October 28th, 2021
- All hopes to save the northern white rhinos now rest on a single female - ZME Science - October 23rd, 2021
- AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1 - StreetInsider.com - October 21st, 2021
- CDMO: The Rise of End-to-End Services - Marketscreener.com - October 21st, 2021
- MeiraGTx Announces the Presentation of Two Novel Inherited - GlobeNewswire - October 21st, 2021
- Current status of drug repositioning in hematology - DocWire News - October 19th, 2021
- Is Fresh Breast Milk Better for Preemies Than Pumped and Stored? - UMass News and Media Relations - October 19th, 2021
- Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem... - October 19th, 2021
- Headband Could Beat Insomnia By Zapping The Brain While Sufferers Wear It For 20 Minutes At Bedtime - - Todayuknews - October 19th, 2021
- BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization -... - October 17th, 2021
- Misinformation on stem cell treatments for COVID-19 linked to overhyped science, researchers argue - EurekAlert - October 17th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - BioSpace - October 17th, 2021
- Nic Chapman: my MS battle and the treatment that's given me hope - The Times - October 17th, 2021
- Dream Body Clinic Stem Cell Therapy Stem Cells HGH - October 13th, 2021
- Hematopoietic Stem Cells - October 13th, 2021
- 3D printing: Healthcare insiders' view on the tech - Verdict - October 13th, 2021
- Top 10 Best Stem Cell Supplement Brands - Healthtrends - October 13th, 2021
- Mitochondrial superoxide dismutase overexpression and low oxygen conditioning hormesis improve the performance of irradiated sterile males |... - October 13th, 2021
- Researchers uncover how cancer cells use sugar residue to evade the immune system - News-Medical.net - October 13th, 2021
- The science and practicality of cultured meat The Stute - The Stute - October 11th, 2021
- Vitro Biopharma Inc. July 31st 2021; 3rd Quarter ended Financial Results of Operations and Shareholder Le - Benzinga - October 11th, 2021
- Want To Support Healthy Bones? It's Time To Get Your Vitamin D In Check - mindbodygreen.com - October 11th, 2021
- Joint : Why Breast Cancer Awareness Matters, and How to Get It Done - marketscreener.com - October 11th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - KY3 - October 7th, 2021